Related Experiment Video
Updated: Aug 6, 2026
09:38
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Aumolertinib Versus Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective
Jinxia Wang1, Ping Qi1, Jinhua Li1
1The First Clinical Medical College of Lanzhou University, Lanzhou, China.
International Journal of Cancer
|August 5, 2026
Summary
Aumolertinib shows superior progression-free survival compared to osimertinib in first-line EGFR-mutant NSCLC treatment. This real-world study found aumolertinib offers better outcomes, especially for specific patient subgroups, with comparable safety profiles.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Third-generation EGFR tyrosine kinase inhibitors (TKIs) are crucial for EGFR-mutant NSCLC.
- Optimal first-line TKI selection remains an area of clinical uncertainty.
- Real-world data is needed to compare aumolertinib and osimertinib efficacy and safety.
Purpose of the Study:
- To compare the real-world efficacy and safety of first-line aumolertinib versus osimertinib.
- To identify potential predictive biomarkers for treatment response in EGFR-mutant NSCLC.
Main Methods:
- Retrospective analysis of 109 EGFR-mutant NSCLC patients (exon 19del/L858R).
- Comparison of first-line aumolertinib (n=53) versus osimertinib (n=56) from 2016-2023.
- Primary endpoints: progression-free survival (PFS) and safety; Secondary endpoints: overall survival (OS), objective response rate (ORR).
Main Results:
- Aumolertinib demonstrated superior median PFS (34.4 months) versus osimertinib (26.9 months; HR 0.52, p=0.031).
- Comparable OS and no significant difference in ORR or overall adverse event rates between groups.
- Aumolertinib showed a lower incidence of liver dysfunction compared to osimertinib.
Conclusions:
- Aumolertinib offers a clinically meaningful PFS advantage over osimertinib in treatment-naïve EGFR-mutant NSCLC.
- Enhanced PFS benefit observed with aumolertinib in exon 19del-mutant and co-mutation-negative populations.
- Aumolertinib's manageable hepatic safety profile supports its clinical utility, warranting further prospective validation.
